Get the Stockscreener App
1.45
2.68%
-0.04
Enlivex Therapeutics Ltd stock is traded at $1.45, with a volume of 250.28K.
It is down -2.68% in the last 24 hours and up +29.46% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.49
Open:
$1.45
24h Volume:
250.28K
Relative Volume:
2.04
Market Cap:
$34.29M
Revenue:
-
Net Income/Loss:
$-22.29M
P/E Ratio:
-1.2288
EPS:
-1.18
Net Cash Flow:
$-17.12M
1W Performance:
+29.23%
1M Performance:
+29.46%
6M Performance:
+31.82%
1Y Performance:
+9.02%
1-Day Range:
$1.41
$1.52
1-Week Range:
$1.16
$1.6592
52-Week Range:
$0.8101
$1.76
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.45 | 35.54M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Can Enlivex Therapeutics Ltd. rally from current levelsPortfolio Building Plan and Summary Guide - Newser
Real time scanner hits for Enlivex Therapeutics Ltd. explainedImmediate Entry Point Prediction Strategy - Newser
Should you wait for a breakout in Enlivex Therapeutics Ltd.Free Capital Growth With Controlled Risk Picks - Newser
Enlivex Therapeutics Ltd. Charts Flash Early Recovery SignalsLow Risk High Return Opportunities Identified - metal.it
Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital - Defense World
Will Enlivex Therapeutics Ltd. stock go up soonPrice Action Trading with Volume Confirmation - Newser
Risk vs reward if holding onto Enlivex Therapeutics Ltd.Technical Chart Summary for Momentum Stocks - Newser
Enlivex Therapeutics Ltd. stock momentum explainedAI Driven Buy Alert Trade Blueprint Released - metal.it
Is Enlivex Therapeutics Ltd. showing signs of accumulationFree Consistent Income Focused Trade List - Newser
What institutional investors are buying Enlivex Therapeutics Ltd. stockLow Risk Strategy With Low Risk - jammulinksnews.com
What indicators show strength in Enlivex Therapeutics Ltd.Real-Time Investment Signal Forecast with AI - Newser
Applying big data sentiment scoring on Enlivex Therapeutics Ltd.Daily Market Movers Screener with Filters - Newser
How Enlivex Therapeutics Ltd. stock performs during market volatilityWeekly Entry Signal Based Forecast Tool - Newser
Top Risks to Consider Before Buying Enlivex Therapeutics Ltd. StockFree Risk Controlled Short Term Trade Plans - Newser
Enlivex Therapeutics (ENLV) Receives Continued Buy Rating with $13 Price Target | ENLV Stock News - GuruFocus
Published on: 2025-07-29 12:00:48 - metal.it
Enlivex Therapeutics (ENLV) Completes Key Trial Stage for Alloce - GuruFocus
Enlivex Completes Key Phase II Trial Milestone for Knee Osteoarthritis Treatment - TipRanks
Enlivex Reaffirms August 18, 2025 As Target Date For Announcemen - GuruFocus
Enlivex Therapeutics Completes Follow-Up for Phase II Trial of Allocetra™ in Knee Osteoarthritis Patients - Quiver Quantitative
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data - The Manila Times
Enlivex Phase II Trial Data for 134 Knee Osteoarthritis Patients Set for August 18 Reveal - Stock Titan
Does Enlivex Therapeutics Ltd. stock perform well during market downturnsAchieve superior capital gains with smart trades - jammulinksnews.com
How Enlivex Therapeutics Ltd. stock performs during market volatility Short-Term Stock Trend Forecast Guide - metal.it
Is Enlivex Therapeutics Ltd. stock overvalued or undervaluedInvest confidently with real-time data analysis - jammulinksnews.com
Is it the right time to buy Enlivex Therapeutics Ltd. stockMaximize your gains with expert trading tips - jammulinksnews.com
What is Enlivex Therapeutics Ltd. company’s growth strategyUncover the best stocks for explosive growth - jammulinksnews.com
How many analysts rate Enlivex Therapeutics Ltd. as a “Buy”Strongest growth potential - jammulinksnews.com
How Resilient Is Enlivex Therapeutics Ltd. Stock During Economic Downturns3x Growth Potential - Newser
What drives Enlivex Therapeutics Ltd. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
Enlivex Therapeutics Ltd. Stock Analysis and ForecastFree Stock Market Query - PrintWeekIndia
What makes Enlivex Therapeutics Ltd. stock price move sharplyValue Pick Scanner - Newser
Is Enlivex Therapeutics Ltd. a good long term investmentExceptional profit velocity - Autocar Professional
What analysts say about Enlivex Therapeutics Ltd. stockExceptional market positioning - jammulinksnews.com
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from Analyst | ENLV Stock News - GuruFocus
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):